Similar articles

• [Experimental and clinical study on the dopaminergic receptor stimulating agents (author's transl)].

  Ohmoto T, Miyamoto T, Baba Y. Ohmoto T, et al. No To Shinkei. 1977 Jul;29(7):?31-40. No To Shinkei. 1977. PMID: 409419 Japanese. No abstract available.
• [New therapeutic indications for a dopamine antagonist, Piribedyl].

  Schmitt H, Laubie M, Poignant JC, Krikorian A, Evrard Y, Freyria JL, Arnaud F. Schmitt H, et al. Sem Hop. 1978 Mar;54(5-8):325-34. Sem Hop. 1978. PMID: 211628 French.
• Weight change during various neuropharmacologic manipulations in psychotic inpatients.

  Carman JS, Wyatt RJ, Nasrallah HA, O'Brien P, Gillin JC. Carman JS, et al. Acta Cient Venez. 1978;29(3):178-80. Acta Cient Venez. 1978. PMID: 757726 No abstract available.
• [The agonist of dopamine receptors piribedil in treatment of Parkinson's disease].

  Pilipovich AA, Golubev VL. Pilipovich AA, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(6):83-90. doi: 10.17116/jnevro20171176183-90. Zh Nevrol Psikhiatr Im S S Korsakova. 2017. PMID: 28745677 Review. Russian.
• DA agonists -- non-ergot derivatives: piribedil: management of Parkinson's disease.

  [No authors listed] [No authors listed] Mov Disord. 2002;17 Suppl 4:S90-2. doi: 10.1002/mds.5568. Mov Disord. 2002. PMID: 12211147 Review. No abstract available.